CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 11 enrolled
Drug / intervention
Liothyronine (T3) +1 moredrug
Likely dose
Liothyronine (T3) 50 microgramsfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00790738
NCT00790738Phase 3Completed
CompareCT.gov

Randomized Double-Blind Trial of Liothyronine (T3) Augmentation to Treatment as Usual vs Placebo For The Treatment of Bipolar Depression

Northwell Health·interventional·Posted Nov 13, 2008·Updated Jul 2, 2015

In Brief

A Phase 3 clinical trial evaluating Liothyronine (T3) and placebo for Depression and Bipolar Disorder. Completed, enrolled 11 participants across 1 site.

Detailed Summary

This study evaluates the efficacy of the thyroid hormone T3 for depression in patients with bipolar disorder. In this study patients will be randomized to receive T3 or placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression, Bipolar Disorder
CountriesUnited States
CollaboratorsNational Alliance for Research on Schizophrenia and Depression

Timeline

Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 13, 2008
Enrollment StartJul 1, 2008
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 17.6 years ago

Interventions

Liothyronine (T3)drug

liothyronine (T3) up to 50 micrograms a day

placebodrug

placebo